MetriDx™
Endometriosis detection and staging
Pre-clinicalActive
Key Facts
About Hera Biotech
Hera Biotech is a private, pre-revenue diagnostics company founded in 2018, pioneering non-invasive solutions for chronic gynecologic conditions. Its core platform consists of two main products: MetriDx™, a molecular test for endometriosis, and HERAfem™, a point-of-care device for cervical lesion detection. The company is addressing a significant market gap characterized by long diagnostic delays, high misdiagnosis rates, and invasive current standards, with initial commercial launches for HERAfem planned for Latin America in 2026. Backed by a team with strong life science exit experience and clinician investors, Hera is positioning itself to set a new diagnostic standard in women's health.
View full company profile